Genetic testing company Natera (NASDAQ: NTRA). will be announcing earnings results this Thursday afternoon. Here’s what to expect.
Natera beat analysts’ revenue expectations last quarter, reporting revenues of $592.2 million, up 34.7% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.
Is Natera a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Natera’s revenue to grow 39.8% year on year, slowing from the 53% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Natera has a history of exceeding Wall Street’s expectations.
With Natera being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, there has been positive investor sentiment in the segment, with share prices up 6.5% on average over the last month. Natera is up 1.6% during the same time .
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
